Anubha Bajaj*

Consultant, Histopathologist, A.B. Diagnostics, India

*Corresponding Author: Anubha Bajaj, Consultant, Histopathologist, A.B. Diagnostics, India.

Received: November 22, 2022; Published: January 01, 2023

Hürthle cell adenoma is a thyroid neoplasm demonstrating follicular architecture with > 75% tumour cells configured as oncocytes which demonstrate intracytoplasmic accumulation of dysfunctional mitochondria. Morphological features as tumour magnitude, nuclear atypia, multinucleated cells, cellular or nuclear pleomorphism, enhanced mitotic activity or definitive histologic configurations appear non indicative of malignant metamorphosis.

Bibliography

1. Mulita F and Anjum F. “Thyroid Adenoma”. Stat Pearls International, Treasure Island, Florida (2022).
2. Zhou X., et al. “Clinical characteristics and prognostic factors of Hurthle cell carcinoma: a population based study”. BMC Cancer1 (2020): 407.
3. Chiapponi C., et al. “Hürthle Cell Carcinoma: Single Center Analysis and Considerations for Surgical Management Based on the Recent Literature”. Frontiers in Endocrinology (Lausanne) 13 (2022): 904986.
4. Yeap ZH., et al. “Synchronous Hürthle cell and medullary thyroid carcinomas”. BMJ Case Report5 (2022): e248879.
5. Image 1 Courtesy: Webpathology.com.
6. Image 2 Courtesy: Pathology outlines.

Citation: Anubha Bajaj. “Fuchsia and Roseate - Hürthle Cell Adenoma". Acta Scientific Clinical Case Reports 4.2 (2023): 01-03.

Copyright: © 2022 Anubha Bajaj. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.